{"organizations": [], "uuid": "be9c255ddfcda84e47ac12a18d399dae78c75229", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/07/globe-newswire-fredas-reaches-definitive-agreement-to-sell-specialty-pharmacy-unit.html", "country": "US", "domain_rank": 767, "title": "Fred’s Reaches Definitive Agreement to Sell Specialty Pharmacy Unit", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.122, "site_type": "news", "published": "2018-05-08T00:05:00.000+03:00", "replies_count": 0, "uuid": "be9c255ddfcda84e47ac12a18d399dae78c75229"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/07/globe-newswire-fredas-reaches-definitive-agreement-to-sell-specialty-pharmacy-unit.html", "ord_in_thread": 0, "title": "Fred’s Reaches Definitive Agreement to Sell Specialty Pharmacy Unit", "locations": [], "entities": {"persons": [{"name": "fred", "sentiment": "negative"}, {"name": "joe anto", "sentiment": "none"}], "locations": [{"name": "tenn.", "sentiment": "none"}, {"name": "memphis", "sentiment": "none"}, {"name": "mississippi", "sentiment": "none"}, {"name": "coldwater", "sentiment": "none"}], "organizations": [{"name": "cvs", "sentiment": "none"}, {"name": "bass berry & sims", "sentiment": "none"}, {"name": "inc.", "sentiment": "none"}, {"name": "covington associates", "sentiment": "none"}, {"name": "cvs health corporation", "sentiment": "none"}, {"name": "about fred’s inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MEMPHIS, Tenn., May 07, 2018 (GLOBE NEWSWIRE) -- Fred's, Inc. (NASDAQ:FRED) announced that it has reached a definitive agreement to sell certain assets of EntrustRx, its specialty pharmacy unit, to a subsidiary of CVS Health Corporation (CVS). The aggregate consideration to be paid is $40.0 million, plus an amount equal to the value of inventory of EntrustRx.\nCommenting on the sale, Fred’s Interim CEO Joe Anto said: “One of Fred’s top priorities for 2018 has been to monetize non-core assets and we are pleased to have reached an agreement for the sale of EntrustRx. The cash proceeds will allow us to pay down a significant portion of our debt and also be used for general corporate purposes.”\nThe transaction is expected to close by the end of May 2018, subject to certain customary closing conditions.\nFred’s was advised on this transaction by Covington Associates and by Bass Berry & Sims.\nAbout Fred’s Inc.\nTracing its history back to an original store in Coldwater, Mississippi, opened in 1947, today Fred’s, Inc. operates approximately 600 general merchandise and pharmacy stores, including 12 franchised locations, and three specialty pharmacy-only locations. With unique store formats and strategies that combine the best elements of a value-focused retailer with a healthcare-focused drug store, Fred’s stores offer frequently purchased items that address the everyday needs of its customers. This includes nationally recognized brands, proprietary Fred’s label products, and a full range of value-priced selections. For more information about the Company, visit Fred’s website at www.fredsinc.com .\nForward Looking Statements\nComments in this news release that are not historical facts are that involve risks and uncertainties that could cause actual results to differ materially from those projected in the A reader can identify because they are not limited to historical facts or they use such words as “outlook,” “guidance,” “may,” “should,” “could,” “believe,” “anticipate,” “plan,” “expect,” “estimate,” “forecast,” “goal,” “intend,” “committed,” “continue,” or “will likely result” and similar expressions that concern the Company’s strategy, plans, intentions or beliefs about future occurrences or results. These risks and uncertainties include, but are not limited to (i) the competitive nature of the industries in which we operate; (ii) the implementation of our strategic plan, and its impact on our sales, costs and operations; (iii) utilizing our existing and new stores and increasing our pharmacy department presence in new and existing stores; (iv) our reliance on a single supplier of pharmaceutical products; (v) our pharmaceutical drug pricing; (vi) reimbursement rates and the terms of our agreements with pharmacy benefit management companies; (vii) our private brands; (viii) the seasonality of our business and the impact of adverse weather conditions; (ix) operational difficulties; (x) merchandise supply and pricing; (xi) consumer demand and product mix; (xii) delayed openings and operating new stores and distribution facilities; (xiii) our employees; (xiv) risks relating to payment processing; (xv) our computer system, and the processes supported by our information technology infrastructure; (xvi) our ability to protect the personal information of our customers and employees; (xvii) cyber-attacks; (xviii) changes in governmental regulations; (xix) the outcome of legal proceedings, including claims of product liability; (xx) insurance costs; (xxi) tax assessments and unclaimed property audits; (xxii) current economic conditions; (xxiii) changes in third-party reimbursements; (xxiv) the terms of our existing and future indebtedness; (xxv) our acquisitions and the ability to effectively integrate businesses that we acquire; (xxvi) our ability to pay dividends; and the factors listed under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and any subsequent quarterly filings on Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made. The Company undertakes no obligation to release revisions to these to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events, except as required to be reported under the rules and regulations of the Securities and Exchange Commission.\nContacts\nFred’s Inc.\nJoe Anto, 901-238-3606\nInterim CEO/ Chief Financial Officer\nLiolios\nSean McGowan or Cody Slach, 949-574-3860\nFRED@liolios.com\nSource:Fred's, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=SYKmIF2NHC-Pou27OWyQ6DYX4xK8RmOqHHkbbifAzmVpu6lJLHAOHTS0ulv-CQ6n2f57Y8X-Z5dInGLC1h9_J1H823AhIPv1-W-ad5lsz0ZmRwfn0biCZBmFMTdmuik8qqvAEcR8OcHuvhokZC08ptg_OJ3QrVTuG3aCACf1Pa-BcUU3S42BWHHkC0TJIb8aaLW8Ggw2Hnk8kc6RMTlQ7M5WNGyVRa2pB7MCyC9-7jKUyhEhWFjybT5uOi9z--xZy2MVMfBXOsj_pV79Z73eqlTZx0_alViwfISN22kSX8lhVIRK98OVNwaflBjVO4_r", "https://www.globenewswire.com/NewsRoom/AttachmentNg/48b0de3f-6ff5-4246-bf9b-86a7eb624be7", "https://www.globenewswire.com/Tracker?data=GLGageX5PGKtxYJ4sULe09YT4sW1ZOJDDuZD6r5MMJA1cTcjUBHGbC_3EDUr8_BTkwoWwis8rMAbObJJ6wjftg=="], "published": "2018-05-08T00:05:00.000+03:00", "crawled": "2018-05-08T00:03:00.015+03:00", "highlightTitle": ""}